FDA Inspection 1209653 — Advagen Holdings, Inc.

Advagen Holdings, Inc. — FEI 3009964119

The FDA completed an inspection of Advagen Holdings, Inc. on Jun 9, 2023 in East Brunswick, NJ. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 8 citations were issued during this inspection. Product area: Drugs.

Inspection details

Classification
Voluntary Action Indicated (VAI)
End Date
Jun 9, 2023
Fiscal Year
2023
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
East Brunswick, NJ (United States)

Citations

IDCFRDescription
110521 CFR 211.22(d)Procedures not in writing, fully followed
122021 CFR 211.67(b)(3)Cleaning SOPs/instructions
150521 CFR 211.122(d)Label storage access limited to authorized personnel
202721 CFR 211.192Investigations of discrepancies, failures
358521 CFR 211.110(a)Control procedures to monitor and validate performance
360321 CFR 211.160(b)Scientifically sound laboratory controls
361621 CFR 211.165(d)Acceptance criteria for sampling & testing
434221 CFR 211.142(b)Storage under appropriate conditions

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.